Andrea Becerril?Gaitan|Bryan F. Vaca-Cartagena|Ana S. Ferrigno|Fernanda Mesa-Chavez|Tonatiuh Barrientos?Gutiérrez|Marco Tagliamento|Matteo Lambertini|Cynthia Villarreal?Garza
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis
Hospital Zambrano Hellion|Tecnológico de Monterrey|Hospital Zambrano Hellion|Tecnológico de Monterrey|Hospital Zambrano Hellion|Tecnológico de Monterrey|Hospital Zambrano Hellion|Tecnológico de Monterrey|Instituto Nacional de Salud Pública|Ospedale Policlinico San Martino|University of Genoa|Ospedale Policlinico San Martino|University of Genoa|Hospital Zambrano Hellion|Tecnológico de Monterrey
patients cancer considered priority group severe acute respiratory syndrome coronavirus 2 sarscov2 vaccination given high risk contracting severe coronavirus disease 2019 covid19 however limited data exist regarding efficacy immunisation population study assess immunologic response covid19 vaccination cancer versus noncancer populationpubmed cochrane central register controlled trials central web science databases searched 01st march 2020 12th august 12 2021 primary endpoints antisarscov2 spike protein immunoglobulin g igg seroconversion rates tcell response documented sarscov2 infection covid19 immunisation data extracted following preferred reporting items systematic reviews metaanalyses prisma guidelines overall effects pooled using randomeffects modelsthis systematic review metaanalysis included 35 original studies overall 51 95 confidence interval ci 4162 73 95 ci 6481 patients cancer developed antis igg threshold level partial complete immunisation respectively patients haematologic malignancies significantly lower seroconversion rate solid tumours complete immunisation 65 vs 94 p 00001 compared noncancer controls oncological patients less likely attain seroconversion incomplete risk ratio rr 045 95 ci 035058 complete rr 069 95 ci 056084 covid19 immunisation schemes patients cancer higher likelihood documented sarscov2 infection partial rr 321 95 ci 0352904 complete rr 204 95 ci 0381110 immunisationpatients cancer impaired immune response covid19 vaccination compared controls strategies endorse completion vaccination schemes warranted future studies aim evaluate different approaches enhance oncological patients immune response